Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Fatty acid-binding protein" patented technology

The fatty-acid-binding proteins (FABPs) are a family of transport proteins for fatty acids and other lipophilic substances such as eicosanoids and retinoids. These proteins are thought to facilitate the transfer of fatty acids between extra- and intracellular membranes. Some family members are also believed to transport lipophilic molecules from outer cell membrane to certain intracellular receptors such as PPAR. The FABPs are intracellular carriers that “solubilize” the endocannabinoid anandamide (AEA), transporting AEA to the breakdown by FAAH, and compounds that bind to FABPs block AEA breakdown, raising its level. The cannabinoids (THC and CBD) are also discovered to bind human FABPs (1, 3, 5, and 7) that function as intracellular carriers, as THC and CBD inhibit the cellular uptake and catabolism of AEA by targeting FABPs. Competition for FABPs may in part or wholly explain the increased circulating levels of endocannabinoids reported after consumption of cannabinoids. Levels of fatty-acid-binding protein have been shown to decline with ageing in the mouse brain, possibly contributing to age-associated decline in synaptic activity.

Inhibitors of fatty acid-binding proteins (FABPs), methods of use, and methods of manufacture

PendingJP2026521144ADyslipidemiaAutoimmune disease
This specification discloses FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases that highly express any of these FABPs, including cancers, particularly triple-negative breast cancer (TNBC), and other pro-inflammatory diseases, including cardiovascular diseases, obesity or obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune disorders, pain, and dementia. This specification also discloses methods for preparing the disclosed compounds.
Owner:CELLORAM INC

Application of fatty acid-binding protein 4 inhibitors in the treatment of heart failure with preserved ejection fraction

ActiveCN116966176Binhibit bindingrelieve symptomsOrganic active ingredientsCardiovascular disorderHeart failure with preserved ejection fractionOral medication
This invention relates to the application of fatty acid-binding protein 4 (FABP4) inhibitors in the treatment of heart failure with preserved ejection fraction. Specifically, the application involves the oral administration of the fatty acid-binding protein 4 (FABP4) inhibitor BMS309403 for the prevention and / or treatment of heart failure with preserved ejection fraction.
Owner:BEIJING INST OF HEART LUNG & BLOOD VESSEL DISEASES

A heart-type fatty acid-binding protein assay kit

ActiveCN224477255UAssayStructural engineering
A kind of heart-shaped fatty acid binding protein determination kit, including box, box cover, fixed seat, movable plate, sleeve, pull plate, mounting bracket, lock sleeve, the box hinge box cover, box cover connects lock tongue, box connects lock seat, lock tongue is adapted to lock seat, lock tongue connects lock seat, the inside connection fixed seat of box, fixed seat has slide, slide is adapted to movable plate, movable plate connects slide, movable plate slides in slide, movable plate has multiple top rods, fixed seat has multiple placement grooves, placement groove is adapted to top rod, top rod connects placement groove, top rod upper portion connects rubber top block, rubber top block connects reagent bottle, reagent bottle connects placement groove.
Owner:TIANJIN KANGERKE BIOSCI